• 出版社/出版日：Mordor Intelligence / 2021年2月25日
|Single User||￥565,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥631,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥997,500 (USD7,500)||▷ お問い合わせ|
The global magnetic resonance imaging market is expected to register a CAGR of nearly 5.5% over the forecast period, with estimated market size of USD 7,550 million in 2020 and expected to reach 10,250 million by 2026.
Amongst the majorly used COVID-19 screening options, imaging is preferred by most healthcare professionals as it provides a primary diagnosis in a short time. All the imaging modalities including magnetic resonance imaging have been used exhaustively to study COVID-19 and its effect on different patients in each demography. Improvements in radiology imaging techniques have enabled the industry to build smaller and portable low-magnetic-field MRIs. People with underlying disease conditions can face more serious complications due to covid. Thus, this will increase the adoption of imaging systems among pandemic. For instance, in 2020, Hyperfine received the United States FDA clearance to use Swoop for brain imaging across all age groups. Thus, rising product approval and adoption impacts the market studied.
The other key factors propelling the growth of the magnetic resonance imaging market are increase in the technological advancements, such as the inclusion of MRI with PET or CT, to provide imaging possibilities with less exposure to harmful radiations, rising adoption of MRI in developing countries, and the rising adoption of universal health coverage in the developed and developing markets.
Magnetic resonance imaging (MRI) is an efficient diagnostic machine for identifying diseases related to tumors, stroke, and spine lesions impacting the area of blood vessels and the brain. The rising prevalence of these diseases is expected to play a crucial role in market growth. For instance, as per the American Cancer Society, in 2020, 19.2 million new cancer cases were recorded across the globe. In addition to this, the rising demand for effective and quick diagnostic procedures is expected to contribute towards the adoption of MRI machines.
The global players, such as GE, Siemens, and Philips, have an extensive hold on improving technology, as well as global distribution channels, which helps the increasing number of public and private diagnostic centers around the world. For instance, in 2019, the US Food and Drug Administration (FDA) approved Clariscan developed by GE Healthcare. Clariscan is a gadolinium-based contrast agent indicated for intravenous use with MRI in brain (intracranial), spine, and associated tissues in adult and pediatric patients, to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Increasing demand and development in the MRI technology is expected to help the market growth. However, the use of refurbished MRI equipment is also widely preferred in the developing markets, due to its cost-effectiveness and easy availability.
Key Market Trends
The Oncology Segment Expected to Hold a Significant Market Share Over the Forecast Period
MRI creates pictures of soft tissue parts of the body that are sometimes hard to see using other imaging tests. As a result, MRI is very good at finding and pinpointing some cancers. An MRI with contrast dye is the best way to see the brain and spinal cord tumors. Using MRI, doctors can sometimes tell if a tumor is cancerous or not.
MRI can also be used to look for signs that cancer may have metastasized (spread) from where it started to another part of the body. MRI images can also help doctors plan treatment, such as surgery or radiation therapy.
The demand for this technology is increasing due to the rising cases of cancer globally. According to Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. As per its 2018 report, if recent trends in incidence of major cancers and population growth are consistent, it is predicted that there will be 27.5 million new cancer cases worldwide each year by 2040. This is an increase of 61.7% from 2018, which is expected to be higher in males, with a rise of about 67.6%, compared to females, with an estimated rise of 55.3%. This factor is expected to increase the demand for MRI in oncology, helping the market grow.
COVID-19 is expected to have a negative impact on the oncology segment from the MRI market. COVID-19 has majorly impacted outpatient imaging services. For instance, as per the article published in NCBI in 2020, “COVID-19 Pandemic Impact on Decreased Imaging Utilization: A Single Institutional Experience”, System-wide imaging volume decreased by 55% between April 7 and 13, 2020. Outpatient exams decreased by 68% relative to normal practice. Emergency exams decreased by 48% and inpatient exams declined by 31%. Mammograms and nuclear medicine scans were the most affected modalities, decreasing by 93% and 61%, respectively.
Also, as per the survey conducted by Breastcancer.org in 2020 among 534 patient population reported that 31.7% of people who had been diagnosed with breast cancer reported a delay in care; of these people, 22% reported that they had a delay in screening and 9.3% reported a delay in treatment due to Covid-19 in the United States. As a result, the wave of more advanced cancers are expected at diagnosis due to delayed biopsies and other issues, such as postponed medical appointments and preventative screening in coming years. Thus, the impact of COVID-19 on the routine diagnostics services industry has been prominent.
North America Dominates the MRI Market and is Expected to Hold the Largest Market Share Over the Forecast Period.
North America currently dominates the magnetic resonance imaging market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the well-established healthcare system of the United States and the initiatives that are being carried out by the various organizations. Siemens and Philips are the leading companies in North America. With that, the United States has the largest market share over the forecast period.
The burden of chronic illnesses, like cancer, cardiovascular diseases (CVD), and neurological diseases, is huge in the United States (US). The Centers for Disease Control and Prevention (CDC) estimates that between 2010 and 2020, the number of new cancer cases in the country may go up about by 24% in men to more than 1 million cases per year, and by about 21% in women to more than 900,000 cases per year. MRI systems are an important part of diagnostics and treatment plans, like radiation therapy. As a result of increasing cancer cases, the demand for MRI is expected to increase in the region.
As a result of this growing demand, many companies have been launching new improved systems to capitalize on the market. In 2017, the U.S. Food and Drug Administration cleared the first seven tesla (7T) magnetic resonance imaging (MRI) device, more than doubling the static magnetic field strength available for use in the United States. The Magnetom Terra is the first 7T MRI system cleared for clinical use in the United States.
The rising number of cases of COVID-19 is expected to have a negative impact on the growth of the North American MRI market. The impact of COVID-19 on the routine diagnostics services industry has been prominent. Governments of various countries have posed restrictions on the usage of MRI, as there are high chances of contamination with the usage of large equipment. In April 2020, the American College of Radiology (ACR) issued a guidance recommendations specifying that radiologists diagnosing the COVID-19 patients should only use the diagnostic imaging equipment only when it is necessary. Furthermore, the guidance recommended that the usage of equipment, like MRI and CT scans, should be temporarily halted to curb the contamination with the virus through diagnostic equipment. However, as the diagnostic imaging instruments, like MRI, represent essential component of healthcare services, the impact is not expected to be long-term.
The global magnetic resonance imaging market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and quality service provision, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Siemens Healthineers, GE Healthcare, Canon Medical Systems, and Philips Healthcare, hold a significant market share in the global magnetic resonance imaging market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Introduction of Hybrid MRI Systems
4.2.2 Availability of Universal Health Coverage in North America, Europe, and Several Asian Countries
4.2.3 Increasing Adoption in Emerging Markets
4.3 Market Restraints
4.3.1 High Cost of MRI Systems
4.3.2 Declining Helium Availability
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Architecture
5.1.1 Closed MRI Systems
5.1.2 Open MRI Systems
5.2 By Field Strength
5.2.1 Low Field MRI Systems
5.2.2 High Field MRI Systems
5.2.3 Very High Field MRI Systems and Ultra-high MRI Systems
5.3 By Application
5.3.6 Other Applications
5.4.1 North America
22.214.171.124 United States (By Architecture, By Field Strength and By Application)
126.96.36.199 Canada (By Architecture, By Field Strength and By Application)
188.8.131.52 Mexico (By Architecture, By Field Strength and By Application)
184.108.40.206 Germany (By Architecture, By Field Strength and By Application)
220.127.116.11 United Kingdom (By Architecture, By Field Strength and By Application)
18.104.22.168 France (By Architecture, By Field Strength and By Application)
22.214.171.124 Italy (By Architecture, By Field Strength and By Application)
126.96.36.199 Spain (By Architecture, By Field Strength and By Application)
188.8.131.52 Rest of Europe (By Architecture, By Field Strength and By Application)
184.108.40.206 China (By Architecture, By Field Strength and By Application)
220.127.116.11 Japan (By Architecture, By Field Strength and By Application)
18.104.22.168 India (By Architecture, By Field Strength and By Application)
22.214.171.124 Australia (By Architecture, By Field Strength and By Application)
126.96.36.199 South Korea (By Architecture, By Field Strength and By Application)
188.8.131.52 Rest of Asia-Pacific (By Architecture, By Field Strength and By Application)
5.4.4 Middle East and Africa
184.108.40.206 GCC (By Architecture, By Field Strength and By Application)
220.127.116.11 South Africa (By Architecture, By Field Strength and By Application)
18.104.22.168 Rest of Middle East and Africa (By Architecture, By Field Strength and By Application)
5.4.5 South America
22.214.171.124 Brazil (By Architecture, By Field Strength and By Application)
126.96.36.199 Argentina (By Architecture, By Field Strength and By Application)
188.8.131.52 Rest of South America (By Architecture, By Field Strength and By Application)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aspect Imaging
6.1.2 Aurora Imaging Technology
6.1.3 Canon Medical Systems Corporation
6.1.4 Carestream Health
6.1.5 Esaote SpA
6.1.6 Fonar Corporation
6.1.7 GE Healthcare
6.1.8 Hitachi Ltd
6.1.9 Koninklijke Philips NV
6.1.10 Neusoft Medical Systems Co. Ltd
6.1.11 Shimadzu Corporation
6.1.12 Siemens Healthcare GmbH
7 MARKET OPPORTUNITIES AND FUTURE TRENDS